Journal
ADVANCES IN ANATOMIC PATHOLOGY
Volume 14, Issue 5, Pages 353-357Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAP.0b013e31814a52c4
Keywords
prostate cancer; AR; androgen ablation; AR coregulators
Categories
Ask authors/readers for more resources
Despite the near ubiquitous use of therapies targeting the androgen receptor (AR) axis in prostate cancer, there remains, at this date, no integrated diagnostic test designed to select and individualize patients for hormonal-based treatments. From the article by Chmelar and coauthors, we may have a glimpse as to a way forward to the development of a test that can successfully guide the use of androgen ablation therapy. By turning our attention away from the AR gene and protein itself and focusing on coregulators of the AR pathway we may have a new opportunity to develop a single or group of slide-based tests designed to assess AR pathway status on the needle biopsy of a newly diagnosed prostate cancer patient and predict the clinical benefit of total androgen blockade treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available